Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?

Immune-checkpoint inhibitors (ICIs) resulted in a revolution in the treatment of progressed non-small cell lung cancer (NSCLC). Blockade of programmed death 1 (PD-1) and its programmed death ligand 1 (PD-L1) has demonstrated better survival rates than cytotoxic chemotherapies.